Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
ELTX

Elicio Therapeutics, Inc.

ELTX

NASDAQ·Healthcare·Biotechnology·Mkt cap $45.9M

$2.41

▼ -3.60%

P/E

-1.13

Mkt Cap

$45.9M

52-Wk Range

$2.36–$16.00

52-Week Range

$2.36 - $16.00

P/E

-1.13

Fwd P/E

-1.18

Beta

1.86

Div Yield

0.00%

Avg Vol

1.6M

Shares Out

18.7M

Mkt Cap

$45.9M

Price action

Price chart

Down 79.4% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary AMP (Amplimune) platform technology with lymph node targeting capability
  • Focused pipeline addressing high-prevalence oncogenic mutations with limited treatment options
  • Clinical-stage validation reducing development risk relative to preclinical competitors
  • Differentiated vaccine approach enabling personalized and combination therapy strategies
▼

Bear Case

1 risk

  • Above-average volatility (beta 1.9).

Growth

Stable outlook

Advancement of ELI-002 through clinical trials with potential for KRAS cancer market expansion

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Falling

-82.2% over 3m

Quality

Loss-making

Below average quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 12, 2026

“
Q3 26 RECAP

AUG 13, 2026

Reported EPS of -$0.43 vs -$0.54 consensus (+20.0% surprise).

EPS beat +20.0%

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+20.0%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

3 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

3

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: HC Wainwright · Jun 15, 2026

View full analyst page →

vs Industry

How ELTX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.